What does Albert David do?

Albert David Ltd manufactures and trades pharmaceutical formulations, infusion solutions, herbal dosage forms, bulk drugs, and disposable syringes and needles. It is a Micro Cap company with a market cap of Rs 460 Cr and reported net sales of 75 Cr and a net loss of 10 Cr for the quarter ending March 2025.

Overview:<BR>Albert David Ltd is engaged in the manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms, bulk drugs, and disposable syringes and needles, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Albert David Ltd was incorporated in 1938 in Calcutta. The company is a unit of the Kothari Group, a prominent industrial house in Kolkata. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 75 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -10 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 460 Cr (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: 27.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 1.43% <BR>Debt Equity: -0.74 <BR>Return on Equity: 4.49% <BR>Price to Book: 1.20 <BR><BR>Contact Details:<BR>Address: D Block 3rd Flr Gillander Hous, Netaji Subhas Road Kolkata West Bengal : 700001 <BR>Tel: 91-33-22302330/2262 8436/8456/ <BR>Email: adidavid@dataone.in <BR>Website: http://www.albertdavidindia.com

When is the next results date for Albert David?

No Upcoming Board Meetings

Has Albert David declared dividend?

Albert David Ltd has declared a 115% dividend, amounting to 11.5 per share, with an ex-date of August 2, 2024. While recent total returns have been negative over the last 6 months and 1 year, longer-term returns show positive growth.

Albert David Ltd has declared a 115% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 115%<BR>- Amount per share: 11.5<BR>- Ex-date: 02 Aug 24<BR><BR>Dividend Yield: 1.43%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -40.98%, the dividend return was 0%, resulting in a total return of -40.98%.<BR><BR>For the 1-year period, the price return was -25.21%, the dividend return was 0.97%, leading to a total return of -24.24%.<BR><BR>Over the 2-year period, the price return was 34.72%, the dividend return was 3.36%, culminating in a total return of 38.08%.<BR><BR>In the 3-year period, the price return was 49.75%, the dividend return was 5.89%, resulting in a total return of 55.64%.<BR><BR>For the 4-year period, the price return was 71.39%, the dividend return was 7.33%, leading to a total return of 78.72%.<BR><BR>In the 5-year period, the price return was 54.4%, the dividend return was 8.61%, culminating in a total return of 63.01%.<BR><BR>Overall, while Albert David Ltd has declared a significant dividend, the recent total returns over shorter periods indicate a challenging performance, particularly in the last 6 months and 1 year. However, the longer-term returns show a more positive trend, suggesting potential recovery and growth.

Who are the peers of the Albert David?

Albert David's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Valiant Laborato, Medico Remedies, Zim Laboratories, and Lyka Labs. In terms of management risk, growth, and capital structure, Albert David shows average performance compared to its peers, with a 1-year return of -30.71%.

Peers: The peers of Albert David are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Valiant Laborato, Medico Remedies, Zim Laboratories, and Lyka Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Lyka Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and Valiant Laborato. Average management risk is present at Albert David, Medico Remedies, and Zim Laboratories. Below Average management risk is noted for Valiant Laborato. In terms of Growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is found at Divi's Lab., Torrent Pharma, Albert David, and Zim Laboratories. Average growth is noted for Medico Remedies and Lyka Labs. Capital Structure ratings show Excellent at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good at Torrent Pharma and Medico Remedies, while Average is seen at Zim Laboratories and Below Average at Valiant Laborato and Lyka Labs.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Valiant Laborato has the lowest at -25.23%. Albert David's 1-year return is -30.71%, which is lower than both of these peers. Additionally, the six-month return is negative for Albert David, Sun Pharma.Inds., Torrent Pharma, Valiant Laborato, Zim Laboratories, and Lyka Labs.

Is Albert David overvalued or undervalued?

As of May 14, 2025, Albert David's valuation has shifted from attractive to risky due to its overvaluation indicated by a high PE ratio of 26.85, an EV to EBITDA ratio of 58.99, and a low ROE of 4.49%, especially when compared to more favorably rated peers like Cipla and Dr. Reddy's Labs, while also underperforming the Sensex with a year-to-date return of -37.28%.

As of 14 May 2025, the valuation grade for Albert David has moved from attractive to risky, indicating a significant shift in its perceived value. The company is currently overvalued, as evidenced by its high PE ratio of 26.85 and an EV to EBITDA ratio of 58.99, which are considerably above industry norms. Additionally, the ROE stands at a low 4.49%, suggesting inefficiencies in generating returns relative to shareholder equity.<BR><BR>In comparison to its peers, Albert David's valuation metrics appear unfavorable. For instance, Cipla, which is rated as attractive, has a PE ratio of 22.99 and an EV to EBITDA of 15.93, while Dr. Reddy's Labs, also attractive, has a PE of 19.49 and an EV to EBITDA of 12.87. The disparity in these ratios highlights the overvaluation of Albert David relative to its competitors. Furthermore, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -37.28% compared to the Sensex's 5.63%, reinforcing the notion of overvaluation.

Is Albert David technically bullish or bearish?

As of July 7, 2025, Albert David's technical trend has shifted to mildly bearish, with daily indicators showing bearish signals and mixed weekly indicators, reflecting a significant decline in performance year-to-date and over the past year.

As of 7 July 2025, the technical trend for Albert David has changed from sideways to mildly bearish. The current technical stance is bearish, with a mild strength indicated by the daily moving averages showing a bearish signal. The weekly MACD and KST are mildly bullish, but the monthly indicators, including MACD and Bollinger Bands, are mildly bearish, suggesting a mixed outlook. The stock's recent performance shows a significant decline year-to-date and over the past year, further supporting the bearish sentiment. Overall, the combination of daily bearish signals and mixed weekly indicators leads to a bearish stance.

Who are in the management team of Albert David?

As of March 2023, the management team of Albert David includes A K Kothari (Executive Chairman), U. M. Kunte (Managing Director & CEO), and directors Prabhawati Devi Kothari and Anand Vardhan Kothari, along with several independent directors and A B Chakrabarty as Company Secretary & Compliance Officer.

As of March 2023, the management team of Albert David includes the following individuals:<BR><BR>1. A K Kothari - Executive Chairman<BR>2. U. M. Kunte - Managing Director & CEO<BR>3. Prabhawati Devi Kothari - Director<BR>4. Anand Vardhan Kothari - Director<BR><BR>Additionally, the board features several independent directors:<BR>1. Hemal Kampani - Independent Director<BR>2. Rajiv Singhi - Independent Director<BR>3. Arindam Sarkar - Independent Director<BR>4. Shirish Gundopant Belapure - Independent Director<BR>5. Monjori Mitra - Independent Director<BR><BR>The company also has A B Chakrabarty serving as Company Secretary & Compliance Officer.

Who are the top shareholders of the Albert David?

The top shareholders of Albert David are Kothari Investment And Industries Private Limited with 41.36%, followed by individual investors at 27.43%. General Insurance Corporation of India is the largest institutional shareholder with 1.61%, while 11 foreign institutional investors hold a combined 1.01%.

The top shareholders of Albert David include Kothari Investment And Industries Private Limited, which holds the largest stake at 41.36%. The company is primarily owned by its promoters, with no pledged promoter holdings reported. Additionally, individual investors collectively hold 27.43% of the shares. Among institutional investors, General Insurance Corporation Of India is the highest public shareholder with a 1.61% stake, while 11 foreign institutional investors (FIIs) hold a combined 1.01%. There is also a small presence of mutual funds, with one scheme holding 0.01%.

How big is Albert David?

As of 24th July, Albert David Ltd has a market capitalization of 522.00 Cr, with recent net sales of 345.77 Cr and a net profit of 17.19 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Albert David Ltd has a market capitalization of 522.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 345.77 Cr, while the sum of Net Profit for the same period is 17.19 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 392.48 Cr and Total Assets totaling 511.42 Cr.

Are Albert David latest results good or bad?

Albert David's latest results are disappointing, with net sales declining 21.03% to Rs 70.57 crore and a loss of Rs -13.60 crore in Profit Before Tax, indicating significant financial challenges and a negative outlook for the company.

Albert David's latest financial results for the quarter ending June 2025 are quite disappointing. The company reported net sales of Rs 70.57 crore, which represents a significant year-on-year decline of 21.03%. This marks the lowest sales figure in the last five quarters, indicating a troubling trend for the business.<BR><BR>Additionally, the Profit Before Tax (PBT) has drastically worsened, with a reported loss of Rs -13.60 crore, reflecting a staggering year-on-year drop of 1260%. The Profit After Tax (PAT) also decreased by 57.9%, amounting to Rs 7.94 crore.<BR><BR>While there is a slight positive aspect in that the company has maintained a Dividend Payout Ratio of 16.59%, the overall financial health appears concerning. The operating cash flow has reached its lowest point in three years at Rs -28.44 crore, raising questions about the sustainability of its operations moving forward.<BR><BR>In summary, the results indicate significant challenges for Albert David, suggesting a negative outlook for the company at this time.

How has been the historical performance of Albert David?

Albert David experienced a decline in financial performance from Mar'24 to Mar'25, with net sales dropping from 362.46 Cr to 345.77 Cr, and profit after tax decreasing from 75.42 Cr to 17.20 Cr, alongside negative cash flow from operating activities. Total assets and liabilities increased, but overall metrics indicate a challenging year.

Answer:<BR>The historical performance of Albert David shows fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Albert David's net sales have varied, with a peak of 362.46 Cr in Mar'24, followed by a decline to 345.77 Cr in Mar'25. The total operating income followed a similar trend, reaching 362.46 Cr in Mar'24 and decreasing to 345.77 Cr in Mar'25. The company's total expenditure, excluding depreciation, increased from 315.58 Cr in Mar'24 to 342.74 Cr in Mar'25. Consequently, the operating profit (PBDIT) saw a significant drop from 104.43 Cr in Mar'24 to 32.61 Cr in Mar'25. Profit before tax also decreased from 97.29 Cr in Mar'24 to 25.23 Cr in Mar'25, leading to a profit after tax of 17.20 Cr in Mar'25, down from 75.42 Cr in Mar'24. The earnings per share (EPS) reflected this decline, falling from 132.08 in Mar'24 to 30.12 in Mar'25. On the balance sheet, total assets rose from 497.99 Cr in Mar'24 to 511.42 Cr in Mar'25, while total liabilities also increased from 497.99 Cr to 511.42 Cr. The cash flow from operating activities turned negative in Mar'25 at -28.00 Cr, contrasting with a positive inflow of 45.00 Cr in Mar'24. Overall, Albert David's financial performance indicates a challenging year in Mar'25 compared to the previous year.

Should I buy, sell or hold Albert David?

Which are the latest news on Albert David?

Why is Albert David falling/rising?

As of 03-Dec, Albert David Ltd's stock price is at 778.70, down 2.27% and nearing its 52-week low. The stock has significantly underperformed, with a year-to-date decline of 41.23%, and is experiencing reduced investor interest, contributing to its bearish trend.

As of 03-Dec, Albert David Ltd's stock price is falling, currently at 778.70, which represents a decrease of 18.05 or 2.27%. The stock has underperformed the sector by 2.26% today and is close to its 52-week low, just 1.9% away from a low of Rs 763.9. Over the past week, the stock has declined by 1.90%, while it has experienced a significant drop of 11.91% over the past month. Year-to-date, the stock is down 41.23%, contrasting sharply with the Sensex, which has gained 8.92% in the same period.<BR><BR>Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. There has also been a notable decline in investor participation, with delivery volume falling by 26.98% compared to the 5-day average. This lack of trading activity suggests a decrease in interest among investors, contributing to the downward pressure on the stock price. Overall, these factors collectively explain the recent decline in Albert David Ltd's stock price.